Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 3/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3496866 | 1.00 | AXL (0.40) | AXLTRPA1EGFRLIPETRPM8 | |
| SCHEMBL31021494 | 0.89 | AXL (0.43) | AXLTRPA1LIPETRPM8TRPV1 | |
| SCHEMBL3497188 | 0.82 | LPL (0.34) | EGFRBRAF | |
| SCHEMBL3496478 | 0.80 | MAPT (0.35) | BRAF | |
| SCHEMBL3496375 | 0.79 | NOS1 (0.36) | BRAF | |
| SCHEMBL15186950 | 0.78 | KDM4E (0.43) | — | |
| SCHEMBL20577550 | 0.77 | KDM4E (0.43) | EGFR | |
| SCHEMBL28782096 | 0.76 | AXL (0.50) | AXLTRPA1TRPM8TRPV1 | |
| SCHEMBL29778034 | 0.74 | MEN1 (0.38) | LIPE | |
| SCHEMBL23275872 | 0.74 | MAPT (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110293-B2 | Substituted triazolo quinoxaline derivatives | Grünenthal GmbH (DE) | 2024-10-08 | — | — | US | disclosed |
| US-20240327416-A1 | Further Substituted Triazolo Quinoxaline Derivatives | GRUENENTHAL GMBH (DE) | 2024-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327416-A1 | Further Substituted Triazolo Quinoxaline Derivatives | NR3C1, GRK5, NR3C2 | AXL 2399/4885TRPA1 2935/4885EGFR 2471/4885 |
| US-12110293-B2 | Substituted triazolo quinoxaline derivatives | NR3C1, NR3C2, GRK5 | AXL 2187/4885TRPA1 2810/4885EGFR 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.